Secondary prevention of cardiovascular disease Circulatory System
Conditions
Interventions
The MIRVAS study is a randomised controlled trial conducted at La Princesa University Hospital. Patients were included in the study between September 2002 and February 2004.
On the day of admission
Sponsors
La Princesa University Hospital (Hospital Universitario de La Princesa) (Spain)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females, from 18 to 80 years old 2. Patients admitted to the hospital for acute coronary syndrome (with or without ST-segment elevation) or an ischaemic stroke
Exclusion criteria
Exclusion criteria: 1. Refusal or inability to participate in the follow-up (displaced patients or with reduced mobility) 2. Life expectancy of less than 12 months 3. Severe cognitive deterioration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following were assessed at three-year follow-up: 1. Cardiovascular mortality and cardiovascular morbimortality, which included the following events: 1.1. Cardiovascular death 1.2. Acute coronary syndrome with or without ST-segment elevation 1.3. Acute stroke (ischaemic or haemorrhagic) 1.4. Revascularisation in any area 1.5. Amputation as a result of peripheral ischaemia 2. Admittance due to heart failure 3. Control of risk factors All episodes were understood as such if they had a clinical report to back them up. The assessments were carried out by an unblinded member of the research group. | — |
Secondary
| Measure | Time frame |
|---|---|
| The following were assessed at 1 and 3 years: 1. Percentage of patients who reached the optimal control of each risk factor 2. Percentage of pharmacological interventions recommended by international guidelines for secondary prevention of cardiovascular risk received in each arm | — |
Countries
Spain
Outcome results
None listed